# ERG

## Overview
The ERG gene encodes the ETS transcription factor ERG, a member of the ETS family of transcription factors, which are characterized by their conserved ETS DNA-binding domain. This protein plays a pivotal role in various cellular processes, including the regulation of endothelial cell quiescence and hematopoietic stem cell homeostasis. As a transcription factor, ERG is involved in modulating gene expression by binding to specific DNA sequences, thereby influencing cellular differentiation, proliferation, and survival. The ERG protein is also implicated in several pathological conditions, most notably in prostate cancer, where gene fusions such as TMPRSS2-ERG result in its overexpression, contributing to oncogenesis and disease progression (Knudsen2015ERG; Lorenzin2022Past). Additionally, ERG's involvement in other malignancies, such as acute myeloid leukemia and Ewing's sarcoma, underscores its significance in cancer biology (Lorenzin2022Past).

## Structure
The ERG protein is a transcription factor belonging to the ETS family, characterized by a conserved ETS DNA-binding domain (EBD) and a pointed (PNT) domain. The EBD is an 85 amino-acid domain featuring a winged helix-turn-helix motif, composed of three α-helices and a four-strand anti-parallel β-sheet. The third α-helix (H3) is crucial for DNA binding, interacting with the major groove of DNA at a core GGA(A/T) motif (Regan2013Structural; Adamo2015The). The PNT domain is a monomeric, five-helix bundle that aids in heterodimerization with other ETS family members and serves as a docking platform for protein kinases (Adamo2015The).

The tertiary structure of ERG is maintained by a hydrophobic core formed by three conserved tryptophan residues within the EBD. The protein also exhibits an autoinhibitory mechanism, where the N-terminal inhibitory domain (NID) and C-terminal inhibitory domain (CID) form a hydrophobic cage around the EBD, inhibiting DNA binding in the absence of DNA (Regan2013Structural; Adamo2015The).

ERG undergoes post-translational modifications, including phosphorylation, which can affect its function and localization. Multiple splice variants of ERG exist, contributing to its diverse roles in cellular processes (Adamo2015The).

## Function
The ERG gene encodes a transcription factor that plays a critical role in maintaining endothelial cell quiescence and hematopoietic stem cell (HSC) homeostasis. In endothelial cells, ERG represses the activity of nuclear factor (NF)-κB p65, a key regulator of proinflammatory gene expression. By binding to specific sites on the promoters of genes such as ICAM-1, IL-8, and cIAP2, ERG inhibits NF-κB p65 from activating these genes, thereby maintaining endothelial cell quiescence and preventing unnecessary inflammatory responses (Dryden2012The). This repression is crucial for endothelial homeostasis, as it protects against the up-regulation of proinflammatory genes (Dryden2012The).

In hematopoietic stem cells, ERG is essential for maintaining the balance between self-renewal and differentiation. It restricts premature differentiation of HSCs, ensuring their maintenance and long-term reconstitution ability. ERG promotes the expression of genes associated with HSC self-renewal while repressing MYC target genes, which are involved in promoting differentiation (Knudsen2015ERG). The loss of ERG function leads to a rapid depletion of HSCs and their progenitors, highlighting its critical role in normal hematopoiesis (Knudsen2015ERG).

## Clinical Significance
The ERG gene is significantly implicated in prostate cancer, primarily through gene fusions such as TMPRSS2-ERG, which lead to ERG overexpression. These fusions are present in approximately 40-50% of prostate cancer cases and are associated with aggressive disease phenotypes, including high-grade prostatic intraepithelial neoplasia and hormone-refractory metastases (Hessels2013Recurrent; Lorenzin2022Past). ERG overexpression, often in conjunction with PTEN loss, contributes to the development of pre-neoplastic lesions and invasive carcinoma by activating oncogenic pathways like WNT/beta-catenin and inhibiting apoptotic signaling (Hessels2013Recurrent; Carver2009Aberrant).

ERG is also involved in other cancers, such as acute myeloid leukemia and Ewing's sarcoma, where its rearrangements or overexpression contribute to tumorigenesis (Lorenzin2022Past). In prostate cancer, ERG's interaction with the androgen receptor and other proteins affects chromatin remodeling and transcriptional regulation, promoting cancer progression (Lorenzin2022Past). The presence of ERG fusions is a potential biomarker for early prostate cancer diagnosis and can predict resistance to certain therapies, such as taxane chemotherapy in castration-resistant prostate cancer (Lorenzin2022Past).

## Interactions
The ERG transcription factor is involved in various protein-protein and protein-DNA interactions that are crucial for its function in cellular processes. ERG interacts with the histone methyltransferase ESET, which is involved in histone H3 methylation, suggesting a role in transcriptional regulation through chromatin modification (Yang2002Molecular). It also forms complexes with the Jun/Fos heterodimer, members of the bZip family, which is essential for transcriptional synergy. This interaction is mediated by direct protein-protein contacts, with the Y371 residue in ERG being critical for this interaction (Camuzeaux2005Imaging).

ERG's DNA-binding activity is modulated by an autoinhibitory mechanism involving specific residues such as Tyr354, which can form hydrogen bonds with DNA bases, highlighting its role in nucleic acid interactions (Regan2013Structural). The protein also interacts with ERK2, a kinase that phosphorylates ERG at the S215 site, a modification necessary for promoting cell migration in prostate cells. This interaction is characterized by a high affinity, allowing ERG to function effectively even under low ERK signaling conditions (Selvaraj2015Comparison). These interactions underscore ERG's involvement in transcriptional regulation and cellular transformation.


## References


[1. (Carver2009Aberrant) Brett S Carver, Jennifer Tran, Anuradha Gopalan, Zhenbang Chen, Safa Shaikh, Arkaitz Carracedo, Andrea Alimonti, Caterina Nardella, Shohreh Varmeh, Peter T Scardino, Carlos Cordon-Cardo, William Gerald, and Pier Paolo Pandolfi. Aberrant erg expression cooperates with loss of pten to promote cancer progression in the prostate. Nature Genetics, 41(5):619–624, April 2009. URL: http://dx.doi.org/10.1038/ng.370, doi:10.1038/ng.370. This article has 528 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng.370)

[2. (Selvaraj2015Comparison) Nagarathinam Selvaraj, Vivekananda Kedage, and Peter C Hollenhorst. Comparison of mapk specificity across the ets transcription factor family identifies a high-affinity erk interaction required for erg function in prostate cells. Cell Communication and Signaling, February 2015. URL: http://dx.doi.org/10.1186/s12964-015-0089-7, doi:10.1186/s12964-015-0089-7. This article has 86 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-015-0089-7)

[3. (Regan2013Structural) Michael C. Regan, Peter S. Horanyi, Edward E. Pryor, Jessica L. Sarver, David S. Cafiso, and John H. Bushweller. Structural and dynamic studies of the transcription factor erg reveal dna binding is allosterically autoinhibited. Proceedings of the National Academy of Sciences, 110(33):13374–13379, July 2013. URL: http://dx.doi.org/10.1073/pnas.1301726110, doi:10.1073/pnas.1301726110. This article has 70 citations.](https://doi.org/10.1073/pnas.1301726110)

[4. (Adamo2015The) P Adamo and M R Ladomery. The oncogene erg: a key factor in prostate cancer. Oncogene, 35(4):403–414, April 2015. URL: http://dx.doi.org/10.1038/onc.2015.109, doi:10.1038/onc.2015.109. This article has 177 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2015.109)

[5. (Dryden2012The) Nicola H. Dryden, Andrea Sperone, Silvia Martin-Almedina, Rebecca L. Hannah, Graeme M. Birdsey, Samia Taufiq Khan, Janice A. Layhadi, Justin C. Mason, Dorian O. Haskard, Berthold Göttgens, and Anna M. Randi. The transcription factor erg controls endothelial cell quiescence by repressing activity of nuclear factor (nf)-κb p65. Journal of Biological Chemistry, 287(15):12331–12342, April 2012. URL: http://dx.doi.org/10.1074/jbc.M112.346791, doi:10.1074/jbc.m112.346791. This article has 66 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M112.346791)

[6. (Yang2002Molecular) Liu Yang, Li Xia, Daniel Y Wu, Hengbin Wang, Howard A Chansky, William H Schubach, Dennis D Hickstein, and Yi Zhang. Molecular cloning of eset, a novel histone h3-specific methyltransferase that interacts with erg transcription factor. Oncogene, 21(1):148–152, January 2002. URL: http://dx.doi.org/10.1038/sj.onc.1204998, doi:10.1038/sj.onc.1204998. This article has 203 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1204998)

[7. (Lorenzin2022Past) Francesca Lorenzin and Francesca Demichelis. Past, current, and future strategies to target erg fusion-positive prostate cancer. Cancers, 14(5):1118, February 2022. URL: http://dx.doi.org/10.3390/cancers14051118, doi:10.3390/cancers14051118. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14051118)

[8. (Knudsen2015ERG) Kasper Jermiin Knudsen, Matilda Rehn, Marie Sigurd Hasemann, Nicolas Rapin, Frederik Otzen Bagger, Ewa Ohlsson, Anton Willer, Anne-Katrine Frank, Elisabeth Søndergaard, Johan Jendholm, Lina Thorén, Julie Lee, Justyna Rak, Kim Theilgaard-Mönch, and Bo Torben Porse. Erg promotes the maintenance of hematopoietic stem cells by restricting their differentiation. Genes &amp; Development, 29(18):1915–1929, September 2015. URL: http://dx.doi.org/10.1101/gad.268409.115, doi:10.1101/gad.268409.115. This article has 72 citations.](https://doi.org/10.1101/gad.268409.115)

[9. (Hessels2013Recurrent) Daphne Hessels and Jack A. Schalken. Recurrent gene fusions in prostate cancer: their clinical implications and uses. Current Urology Reports, 14(3):214–222, April 2013. URL: http://dx.doi.org/10.1007/s11934-013-0321-1, doi:10.1007/s11934-013-0321-1. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11934-013-0321-1)

[10. (Camuzeaux2005Imaging) Barbara Camuzeaux, Corentin Spriet, Laurent Héliot, Jean Coll, and Martine Duterque-Coquillaud. Imaging erg and jun transcription factor interaction in living cells using fluorescence resonance energy transfer analyses. Biochemical and Biophysical Research Communications, 332(4):1107–1114, July 2005. URL: http://dx.doi.org/10.1016/j.bbrc.2005.05.057, doi:10.1016/j.bbrc.2005.05.057. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2005.05.057)